Effects of Rhubarb on Intestinal Dysmotility in Critically Ill Patients

Kentaro Shimizu¹, Mitsuru Kageyama², Hiroshi Ogura¹, Tomoki Yamada¹ and Takeshi Shimazu¹

Abstract:
Intestinal dysmotility is a major problem in critically ill patients. This report describes the successful treatment of intestinal dysmotility with rhubarb as a laxative in six critically ill patients on mechanical ventilation. Bowel movement and defecation occurred in all patients an average of 1.8 days after the administration of powdered rhubarb. In 4 patients who also had gastric reflux, the reflux volume via nasal tube was decreased an average of 3.5 days after the initiation of rhubarb treatment, and enteral nutrition was able to be started. Rhubarb may be useful for the treatment of incompetent gastric and intestinal motility in critically ill patients.

Key words: critically ill, constipation, defecation, ICU, motility

(Intern Med 57: 507-510, 2018)
(DOI: 10.2169/internalmedicine.8878-17)

Introduction

Intestinal complications such as diarrhea and intestinal dysmotility as indicated by symptoms such as gastric fluid reflux, constipation, and vomiting occur in 60% or more of patients in the intensive-care unit (ICU). Constipation is also reported to occur in 2% to 25% of healthy people, but the incidence sometimes rises to 80% in critically ill patients (1). Although enteral nutrition is recommended in the early stage for critically ill patients (2), it is not possible to conduct enteral nutrition in patients with intestinal dysmotility. Furthermore, intestinal dysmotility can result in intestinal “undrained abscess” due to the abnormal proliferation of pathogenic bacteria, which can easily cause bacterial translocation leading to septic conditions and multiple organ dysfunction syndrome (3). It has been reported that constipation in ICU patients is related to prolongation of hospitalization and an increase in mortality (4, 5).

Rhubarb has been widely used as a traditional Chinese herbal medicine since ancient times. Sennoside A and other dianthrone derivatives are reported to be the active ingredients causing rhubarb’s laxative effect (6). They are metabolized by β-glucosidase of entrobacterial origin and are converted into rhein anthrone, which produces the purgative activity. This is also known to have an antibacterial effect (7) and effects on nitrogen urea metabolism (8) and renal protection (9, 10). Rhubarb, which can be used as a prescribed drug “Powdered Rhubarb” (11) (Daio powder; Suzu Pharmaceutical, Osaka, Japan) in Japan, can be administered for constipation.

However, there have been few reports on the effects of rhubarb therapy in critically ill patients. Therefore, we examined the effects of rhubarb in the treatment of intestinal dysmotility in critically ill patients.

Case Reports

Case 1

A 69-year-old man was transferred from another hospital because of sepsis. When he arrived, his heart rate was 95/min, and his blood pressure was 154/81 mmHg with catecholamine therapy. His respiratory rate was 22/min, but an arterial blood gas analysis yielded a pH of 7.49, partial pressure of carbon dioxide in arterial blood (PaCO₂) of 47.6 mmHg, and partial pressure of arterial oxygen (PaO₂) of 60.3 mmHg under oxygen support. He was intubated, and...
intensive care was required.

A blood culture revealed *Stenotrophomonas maltophilia*, and laboratory tests revealed a white blood cell count of 20,700/mm³, red blood cell count of 237×10⁶/mm³, hemoglobin of 7.3 g/dL, hematocrit of 24.3%, and platelet count of 63×10⁹/mm³. Sepsis was diagnosed, and carbapenem antibiotics were started. On day 3, a laxative (sodium picosulfate hydrate) was administered because he had had no stools for 3 days. There was still no defecation on day 4, so rhubarb was started. On the morning of the following day, he had several stools. He subsequently continued defecation without the use of laxatives and recovered.

**Case 2**

A 74-year-old man was admitted with necrotizing fasciitis in the neck and mediastinum. His vital signs were heart rate 92/min, respiratory rate 23/min, blood pressure 156/62 mmHg, and blood temperature 36.2°C. Although his vital signs were relatively stable, his pH was 7.25 and blood lactate was 19 mg/dL. His white blood cell count was 13,720/mm³ with no anemia, and his C-reactive protein level was 24 mg/dL. He had severe systemic inflammation, and his metabolic acidosis progressed. He was intubated for a procedure, and catheter drainage was performed from the neck to the mediastinum. Blood culture revealed methicillin-resistant *Staphylococcus epidermidis* and *Enterococcus* from the catheter, so vancomycin and meropenem were administered. Enteral nutrition was started on day 2, but there had been no stools. On day 4, powdered rhubarb 0.5 g 3 times/day was started. The next day, he defecated 4 times. He continued to tolerate the rhubarb safely for 34 days with continued defecation.

We also retrospectively reviewed the mechanically ventilated critically ill patients listed in Table, which included 6 patients (5 men, 1 woman; mean age, 65.2±6.1 years). Three patients had acute respiratory distress syndrome, and the other three had infectious diseases. The mean Acute Physiology and Chronic Health Evaluation (APACHE) II score on admission was 15.3±4.1 (12). No adverse events occurred in any patient. The average number of days of constipation before using rhubarb was 5.8 (range: 3-11 days). Bowel movement and defecation occurred in all patients within an average of 1.8 (range: 1-4) days after administration of the powdered rhubarb. In 4 patients who also had gastric reflux, the average reflux was 375 (range: 200-800) mL/day. The reflux volume via nasal tube decreased an average of 3.5 (range: 1-5) days after the initiation of the rhubarb treatment, and enteral nutrition was able to be continued in three patients and started in another three patients.

### Discussion

This is the first study to evaluate the effects of rhubarb in the treatment of intestinal dysmotility in critically ill patients with mechanical ventilation. All of the patients in our study defecated within 1.8 days after beginning the use of rhubarb, and 5 of the 6 patients defecated within 2 days of its administration. There were no side effects. These results suggest that rhubarb may be a promising agent for improving constipation.

In intensive care, from the viewpoint of infection prevention and improvement of immunity, enteral nutrition is recommended from an early stage, even in patients undergoing mechanical ventilation (13). It is therefore important to control intestinal motility in critically ill patients. In severe cases, decreased intestinal blood flow due to shock, hypoxemia, and other additional stresses decreases intestinal motility and induces constipation (14). Short-chain fatty acids (SCFAs) are the metabolic end products of microbiota, and they have effects on gastrointestinal motility. Disruption of the fecal microbiota and SCFAs occurs within six hours after admission (15), and these changes remain low for six weeks (16). These miscellaneous factors may contribute to the extent of refractory constipation. For treatment of constipation in intensive care, van der Spoel et al. reported that polyethylene glycol and lactulose were effective for improv-
ing constipation in 208 ICU patients with multiple organ failure (17). Further studies are needed to compare the effects of rhubarb with these agents.

The laxative mechanism of rhubarb is based on the enhancement of the motility and secretion of water and electrolytes. Frixinos et al. measured the myoelectrical activity of the descending and sigmoid colon in humans and showed that sennoside stimulates peristaltic activity (18). Beubler and Kollar reported that intraluminal prostaglandin E2 is increased by the administration of sennoside, resulting in water and electrolyte secretion (19). These effects were inhibited by indomethacin. Another involved mechanism is an antibacterial effect. Rhubarb has been reported to exert anti-bacterial activity against Bacteroides fragilis (7) and to inhibit cholera toxin activities, including adenosine diphosphate (ADP)-ribosylation and the accumulation of intraluminal fluid (20).

To induce its laxative effect, rhubarb needs to be metabolized to rhein anthrone by β-glucosidase, which is produced by gut microbiota. Nijs et al. reported that germ-free rats have a larger cecal weight and longer intestinal transit time and receive no laxative effect from rhein anthrone than the rats which have gut microbiota (21). The difference in laxative effects based on the gut microbiota is expected. Indeed, when intestinal flora in patients with systemic inflammatory response syndrome are quantitatively assessed, the total numbers of obligate anaerobes are significantly lower than those of normal controls, and this is associated with mortality (22, 23). In terms of the mechanism of absorption, Kon et al. reported that rhein anthrone activates macrophages, which can reduce the aquaporin-3 expression, inhibit the absorption of water, and lead to a laxative effect (24). Thus, periods of constipation may depend on both the severity of disease and the SCFAs generated by the altered microbiota. In addition, periods of defecation may depend on the β-glucosidase generated by the altered microbiota and water transporter dysfunction in the colon. Consequently, the purgative effects of rhubarb may vary by patient.

In the present study, even when patients were so severely infected they experienced reflux of gastric juice, not only did the administration of rhubarb improve bowel movements, but it also decreased the reflux volume, suggesting an effect of rhubarb on the upper digestive tract. Recently, maintenance of intestinal motility has become an important issue in intensive-care medicine. Although drugs such as metoclopramide, erythromycin, neostigmine, and others are reported to resolve incompetent intestinal motility (25), there are problems with drug tolerance. Patients with feeding intolerance have lower numbers of total obligate anaerobes than do patients without feeding intolerance, which is associated with mortality (26). Such situations in which the continuous reflux of gastric juice prevents successful enteral nutrition can result in an unfavorable condition from the viewpoint of wound healing or immunodeficiency. A Japanese kampo medicine called rikkunshito has been found to be effective for treating such functional gastrointestinal disorders and is also reported effective for gastric juice reflux in intensive-care patients (27, 28). In our patients, the action of rhubarb to stimulate intestinal motility may also have worked on the upper digestive tract and thereby decreased gastric juice reflux. The gastric juice reflux observed in four of our patients stopped before enteral nutrition began. The mechanism underlying these effects is a subject for future investigation, but rhubarb may contain motile ingredients that act on the upper gastrointestinal system in addition to its laxative effect. Rhein anthrone or its combination with pre-existing motility drugs might attenuate drug tolerance. As a limitation of this study, we could not start treatment with the same timing in all cases because this is a retrospective case report, and the number of days of constipation before treatment differed among patients. Further prospective studies are needed to clarify the effects of rhubarb.

Improvement in intestinal motility can prevent sepsis of gut origin (29). Wan et al. reported that, in 126 patients with severe acute pancreatitis treated with enteral nutrition and rhubarb, the abdominal condition recovered relatively early, and the levels of plasma C-reactive protein and IL-6 were significantly decreased (30).

In conclusion, the present study suggested that rhubarb was useful for treating incompetent intestinal motility in patients with systemic inflammatory response syndrome. Further clinical studies of rhubarb are required to determine the indications and suitability of rhubarb as a new therapy for intestinal dysmotility and constipation in critically ill patients.

The authors state that they have no Conflict of Interest (COI).

References

1. Mostafa SM, Bhandari S, Ritchie G, et al. Constipation and its implications in the critically ill patient. Br J Anaesth 91: 815-819, 2003.
2. Martindale RG, McClave SA, Vanek VW, et al. Guidelines for the provision and assessment of nutrition support therapy in the critically ill patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition: executive summary. Crit Care Med 37: 1757-1761, 2009.
3. Marshall JC, Christou NV, Meakins JL. The gastrointestinal tract. The “undrained abscess” of multiple organ failure. Ann Surg 218: 111-119, 1993.
4. van der Spoo JI, Schultz MJ, van der Voort PH, et al. Influence of severity of illness, medication and selective decontamination on defecation. Intensive Care Med 32: 875-880, 2006.
5. Asai T. Constipation: does it increase morbidity and mortality in critically ill patients? Crit Care Med 35: 2861-2862, 2007.
6. Peigen X, Liyi H, Liwei W. Ethnopharmacologic study of Chinese rhubarb. J Ethnopharmacol 10: 275-293, 1984.
7. Cyong J, Matsamoto T, Arakawa K, et al. Anti-Bacteroides fragilis substance from rhubarb. J Ethnopharmacol 19: 279-283, 1987.
8. Mitsuma T, Yokozawa T, Oura H, et al. [Rhubarb therapy in patients with chronic renal failure (Part 2)]. Nihon Jinzo Gakkai Shi 29: 195-207, 1987 (in Japanese, Abstract in English).
9. Wang J, Zhao Y, Xiao X, et al. Assessment of the renal protection and hepatotoxicity of rhubarb extract in rats. J Ethnopharmacol 124: 18-25, 2009.
10. Shibutani S, Nagasawa T, Oura H, et al. Mechanism of the blood urea nitrogen-decreasing activity of rhatannin from Rhei Rhizoma in the rat. I. Chem Pharm Bull (Tokyo) 31: 2378-2385, 1983.
11. The Japanese Pharmacopoeia (Sixteenth Edition). Minister of Health, Labour and Welfare 2011 [cited 2017 May 24]. Available from: http://jpdb.nih.go.jp/kyokuhou/archives-e.htm
12. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20: 864-874, 1992.
13. Herbert MK, Holzer P. Standardized concept for the treatment of gastrointestinal dysmotility in critically ill patients-current status and future options. Clin Nutr 27: 25-41, 2008.
14. Caddell KA, Martindale R, McClave SA, et al. Can the intestinal dysmotility of critical illness be differentiated from postoperative ileus? Curr Gastroenterol Rep 13: 358-367, 2011.
15. Hayakawa M, Asahara T, Henzan N, et al. Dramatic changes of the gut flora immediately after severe and sudden insults. Dig Dis Sci 56: 2361-2365, 2011.
16. Yamada T, Shimizu K, Ogura H, et al. Rapid and sustained long-term decrease of fecal short-chain fatty acids in critically ill patients with systemic inflammatory response syndrome. JPEN J Parenter Enteral Nutr 39: 569-577, 2015.
17. van der Spoel JJ, Oudemans-van Straaten HM, Kuiper MA, et al. Laxation of critically ill patients with lactulose or polyethylene glycol: a two-center randomized, double-blind, placebo-controlled trial. Crit Care Med 35: 2726-2731, 2007.
18. Frexininos J, Staumont G, Fioramonti J, et al. Effects of sennosides on colonic myoelectrical activity in man. Dig Dis Sci 34: 214-219, 1989.
19. Beubler E, Kollar G. Prostaglandin-mediated action of sennosides. Pharmacology 36 (Suppl 1): 85-91, 1988.
20. Oi H, Matsura D, Miyake M, et al. Identification in traditional herbal medications and confirmation by synthesis of factors that inhibit cholera toxin-induced fluid accumulation. Proc Natl Acad Sci U S A 99: 3042-3046, 2002.
21. Nijs G, De Witte P, Geboes K, et al. Conventionalization of germ-free rats reverses the disability of rhein anthrone to induce laxation. Eur J Pharmacol 239: 241-243, 1993.
22. Shimizu K, Ogura H, Goto M, et al. Altered gut flora and environment in patients with severe SIRS. J Trauma 60: 126-133, 2006.
23. Shimizu K, Ogura H, Hamasaki T, et al. Altered gut flora are associated with septic complications and death in critically ill patients with systemic inflammatory response syndrome. Dig Dis Sci 56: 1171-1177, 2011.
24. Kon R, Ikarashi N, Nagoya C, et al. Rheinanthrone, a metabolite of sennoside A, triggers macrophage activation to decrease aquaporin-3 expression in the colon, causing the laxative effect of rhubarb extract. J Ethnopharmacol 152: 190-200, 2014.
25. Nguyen NQ, Chapman M, Fraser RJ, et al. Prokinetic therapy for feed intolerance in critical illness: one drug or two? Crit Care Med 35: 2561-2567, 2007.
26. Shimizu K, Ogura H, Asahara T, et al. Gastrointestinal dysmotility is associated with altered gut flora and septic mortality in patients with severe systemic inflammatory response syndrome: a preliminary study. Neurogastroenterol Motil 23: 330-335, e157, 2011.
27. Tatsumi H, Matsuda Y, Imaizumi H, et al. Usefulness of the traditional Chinese medicine rikkunshito for improving delayed gastric emptying in critically ill patients - Report of three cases. J Jpn Soc Intensive Care Med 16: 187-190, 2009 (in Japanese, Abstract in English).
28. Hayakawa M, Ono Y, Wada T, et al. Effects of Rikkunshito (traditional Japanese medicine) on enteral feeding and the plasma ghrelin level in critically ill patients: a pilot study. J Intensive Care 2: 53, 2014.
29. Chen DC, Wang L. Mechanisms of therapeutic effects of rhubarb on gut origin sepsis. Chin J Traumatol 12: 365-369, 2009.
30. Wan B, Fu H, Yin J, et al. Efficacy of rhubarb combined with early enteral nutrition for the treatment of severe acute pancreatitis: a randomized controlled trial. Scand J Gastroenterol 49: 1375-1384, 2014.

The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).